Obesity and diabetes mellitus in the Arab world  by Alzaman, Naweed & Ali, Asem
Taibah University
Journal of Taibah University Medical Sciences (2016) 11(4), 301e309Journal of Taibah University Medical Sciences
www.sciencedirect.comReview ArticleObesity and diabetes mellitus in the Arab world
Naweed Alzaman, MDa,* and Asem Ali, MDb
aCollege of Medicine, Department of Internal Medicine, Taibah University, Almadinah Almunawwarah, KSA
bUMass Memorial Medical Center, Worcester, MA, USAReceived 1 December 2015; revised 15 March 2016; accepted 17 March 2016; Available online 20 May 2016ﺍﻟﻤﻠﺨﺺ
ﺃﺩﺕﺍﻟﺴﻤﻨﺔﺇﻟﻰﺯﻳﺎﺩﺓﺍﻧﺘﺸﺎﺭﺩﺍﺀﺍﻟﺴﻜﺮﻱﻣﻦﺍﻟﻨﻮﻉ٢ﺑﻴﻦﺍﻟﺸﻌﻮﺏﺍﻟﻌﺮﺑﻴﺔﻋﻠﻰ
ﻣﺪﻯﺍﻟﻌﻘﺪﻳﻦﺍﻟﻤﺎﺿﻴﻴﻦ.ﻭﻗﺪﻭﺿﺤﺖﺍﻟﺒﺤﻮﺙﺃﻥﺍﻟﺴﻤﻨﺔﺗﺼﺎَﺣﺐﺑﻤﻘﺎﻭﻣﺔ
ﺍﻷﻧﺴﻮﻟﻴﻦ،ﻭﺣﻴﻨﻤﺎﺗﻘﺘﺮﻥﻫﺬﻩﺍﻟﻤﻘﺎﻭﻣﺔﻣﻊﻧﻘﺺﻫﺮﻣﻮﻥﺍﻷﻧﺴﻮﻟﻴﻦ،ﻳﺆﺩﻳﺎﻥﺇﻟﻰ
ﺩﺍﺀﺍﻟﺴﻜﺮﻱﻣﻦﺍﻟﻨﻮﻉ٢.
ﻭﻗﺪﺗﻨﺎﻭﻟﻨﺎﻓﻲﻫﺬﻩﺍﻟﻤﺮﺍﺟﻌﺔﺍﻟﺪﺭﺍﺳﺎﺕﺍﻟﻤﻨﺸﻮﺭﺓﻋﻦﺍﻧﺘﺸﺎﺭ،ﻭﻋﻮﺍﻣﻞﺧﻄﺮ،
ﺍﻟﺴﻤﻨﺔ،ﻭﺍﻟﺠﻴﻨﺎﺕﺍﻟﻮﺭﺍﺛﻴﺔﻟﻠﺴﻤﻨﺔﻓﻲﺍﻟﺸﻌﻮﺏﺍﻟﻌﺮﺑﻴﺔ،ﻭﻛﺬﻟﻚﺁﻟﻴﺔﺣﺼﻮﻝ
ﺍﻟﺴﻤﻨﺔ.ﻛﻤﺎﺗﻄﺮﻗﻨﺎﺇﻟﻰﺍﻟﻌﻮﺍﺋﻖﺍﻟﺘﻲﻳﻮﺍﺟﻬﻬﺎﻣﺮﻳﺾﺍﻟﺴﻤﻨﺔﻓﻲﺍﻟﻌﺎﻟﻢﺍﻟﻌﺮﺑﻲ
ﻟﻠﺘﺨﻠﺺﻣﻦﺍﻟﻮﺯﻥﺍﻟﺰﺍﺋﺪ،ﻭﺃﻟﻘﻴﻨﺎﺍﻟﻀﻮﺀﻋﻠﻰﺍﺳﺘﺮﺍﺗﻴﺠﻴﺎﺕﻋﻼﺝﺍﻟﺴﻤﻨﺔﻓﻲ
ﺍﻟﺸﻌﻮﺏﺍﻟﻌﺮﺑﻴﺔ.
ﺍﻟﻜﻠﻤﺎﺕﺍﻟﻤﻔﺘﺎﺣﻴﺔ:ﺍﻟﺴﻤﻨﺔ؛ﺩﺍﺀﺍﻟﺴﻜﺮﻱﻣﻦﺍﻟﻨﻮﻉ٢؛ﺍﻟﻌﺮﺏ
Abstract
Obesity has led to a dramatic increase in the incidence of
type 2 diabetes mellitus among the Arab population over
the past 2 decades. Obesity is strongly associated with
insulin resistance, which, when coupled with relative in-
sulin deficiency, leads to the development of overt type 2
diabetes mellitus. This comprehensive review summarizes
the key findings in the published literature pertaining to
the prevalence, risk factors, and genetics of obesity in the
Arab population. The mechanisms of obesity-associated
diabetes mellitus are also elaborated. In addition, we
have reviewed several management strategies and the
perceived barriers to their effectiveness in obese Arabs.* Corresponding address:Department of InternalMedicine, Taibah
University Medical College, Almadinah Almunawwarah, KSA.
E-mail: naweedalzamanmd@gmail.com (N. Alzaman)
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Overweight and obesity are defined as abnormal or
excessive fat accumulation that may impair health. Body
mass index (BMI) is a simple index of weight-for-height that
is commonly used to classify overweight and obesity in
adults. It is defined as a person’s weight in kilograms divided
by the square of his height in meters (kg/m2). BMI greater
than or equal to 25 is considered to be overweight, and BMI
greater than or equal to 30 is considered to be obesity,3 which
is divided into 3 classes. Class I obesity is BMI 30e35 kg/m2,
Class II obesity is BMI 35e40 kg/m2 and Class 3 is severe
obesity, which is BMI greater than or equal to 40 kg/m2.
Figure 1A shows WHO age-standardized mean BMI esti-
mates of different Arab countries in 2010 for males, and
Figure 1B shows these estimates for females.
Waist circumference provides information on central
adiposity beyond that provided by BMI. Central adiposity
correlates well with visceral adiposity, which elevates the risk
for such obesity-related diseases as diabetes, hypertension,
and nonalcoholic fatty liver disease. Waist circumference
should be measured over the iliac crests in a horizontal plane
after the patient exhales following a normal breath. A waist
circumference of 35 inches (88 cm) for women and 40
inches (102 cm) for men is considered elevated.3
Prevalence of obesity in the Arab world
Several studies have addressed the prevalence of obesity
and diabetes in different Arab countries. The prevalence ofhis is an open access article under the CC BY-NC-ND license
16/j.jtumed.2016.03.009
Figure 1: A. Mean BMI distribution of Arab World Males. B. Mean BMI distribution of Arab World Females.
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the Arabian Gulf, is related to a significant growth in income
from rich deposits of oil reserves and resulting rapid ur-
banization and improved living conditions. In 2014, the
World Health Organization (WHO) released a data report
on BMI and obesity prevalence in both genders that showed
that in most Arab countries, the prevalence is mostly
increasing compared to 2010.4 This can be a substantial
health crisis given that obesity is the 6th most important
risk factor for worldwide disease burden.5 Over the last 2decades, several studies were performed to determine the
prevalence of obesity. The sample sizes in those studies
ranged from several hundreds to almost 20,000 participants.
Bacchus et al.6 found that 65% of patients with diabetes
were overweight in 1982, while in 1987, Fatani et al.7
found that 41% of a diabetes patient population was
obese. Both of those studies were performed in rural areas.
In Bahrain in 1996 Farouq et al.8 found that the
prevalence of obesity reached up to 32% in patients with
diabetes compared to 24% in controls. In 1997 a group in
Obesity in Arabs 303KSA found that diabetes was diagnosed in 26% and 23% of
obese males and females, respectively, compared to 8% and
4% non-obese males and females, respectively.9 Others used
waist circumference to define obesity,1 where central obesity
was one of the characteristics in 33% of males with diabetes
and 27% of females. More recently in the Aseer10 region of
KSA, it was concluded that most of the DM and HTN
patients in primary health care centres suffer from
overweight and obesity, which significantly contributed to
poorly controlled DM and HTN, with percentages
reaching up to 60e70%. The difference between the
current studies and the above-mentioned studies might be
explained by the increasing prevalence of obesity and over-
weight observed during the last decade that resulted from a
sedentary lifestyle and consumption of a diet rich in simple
carbohydrates and fat, as well as other factors. Table 1 shows
diabetes and obesity prevalence according to the World
Health Organization and International Diabetes Federation.
Childhood obesity generally persists through adulthood.
Approximately one-third (26% male, 41% female) of obese
Arabic-speaking preschool children and half (42%male 63%
female) of obese school-age children were also obese at
adulthood according to a survey of data collected between
1970 and 1992.11 More recently, a retrospective hospital-
based, cross-sectional study assessed the prevalence of
T2DM among children and adolescents in Khartoum,
Sudan.12 Among 958 children registered at the diabetes
referral centre, 38 were diagnosed with Type 2 diabetes, the
majority of whom were aged 11e18 years. The female-to-
male ratio was 1.2:1, and obesity was present in 29 out of
38 children with T2DM, with another 8 children being
overweight. The majority (32/38) of children with T2DM in
this report were from tribes of Arab origin. These data about
the occurrence of diabetes in children and adolescents were
also confirmed in other cross-sectional studies that reported
a very high prevalence of overweight and obesity amongTable 1: Prevalence of obesity and diabetes in Arabic-speaking
countries.
Country WHO obesitya IDF diabetesb
Male Female Both genders
Kuwait 30% 55% 23%
UAE 25% 42% 19%
KSA 23% 36% 24%
Egypt 22% 48% 17%
Bahrain 21% 38% 22%
Jordan 20% 38% 11%
Qatar 19% 32% 20%
Lebanon 15% 27% 15%
Libya 12% 25% 10%
Syria 12% 25% 9%
Iraq 8% 19% 10%
Tunisia 8% 33% 9%
Oman 8% 17% 15%
Algeria 6% 16% 7%
Morocco 4% 23% 8%
Yemen 2% 2% 8%
Sudan 2% 7% 18%
a World Health Organization statistics 2010.
b International Diabetes Federation statistics 2014.Arab male adolescents, ranging from 13% in Algeria to 60%
in Kuwait.13,14 A similar prevalence of obesity and
overweight occurred in females, with 16% of Palestinian
and 41% of Kuwaiti adolescent girls being affected.Risk factors
The aetiology of obesity is far more complex than simply
an imbalance between energy intake and energy output.
Metabolic, endocrine, and genetic factors; dietary habits;
physical activity; race; age; sex; drug use; and socioeconomic
status all play a role in the development of obesity.
The rise of obesity in the Arab world is due to several
factors, including the accessibility of private cars, employ-
ment of housemaids, and population as a whole engaging in
less physical activity. The rise in caloric and fat intake in a
region where exercise is not a defining part of the culture has
added to the overall increased percentages of overweight and
obese populations.15 In addition, women are more likely to
be overweight or obese due to cultural norms.9 Most
studies performed in this region that searched for factors
that increase obesity risk were cross-sectional and focused
on limited factors. It is difficult to interpret and compare
countries, or even subjects within the same country, because
of the various questionnaire formats used by different
studies.16
One of themore significant factors influencing obesity rates
is a change in food consumption, as dietary habits have
changed markedly during the past four decades because of
increased calorie supply17; this has been studied in different
countries across the region. Consuming high-fat Westernized
fast food or local fast food contribute to obesity in a similar
way,18 so it is difficult to blame the Western diet alone for
increased obesity in the Arab world. Eating foods prepared
outside the home is a serious contributing factor. Amin
et al.19 found that as eating outside the home increased in
primary school children (6e11 years), the proportion of
obesity increased. Among those who ate home-prepared
meals, 9.4% were obese and the rest were non-obese. The
proportion of obesity increased to reach 52.7% among those
who ate outside the home more than 5 times per week. The
association between eating out and obesity among these chil-
dren was highly significant (P < 0.001).
Protective dietary behaviours are important factors in
preventing obesity and diabetes. It is well known that con-
sumption of fibre, fruits and vegetables decrease the risk of
obesity. A study among university students in Kuwait
revealed that regular consumption of fruits and vegetables
was a protective factor against obesity.20 Eating breakfast is
another factor that is associated with a reduced risk of
becoming overweight or obese.21 There are few studies
exploring this relationship in the Arab world.
Urbanization is another factor that increases obesity.1,22
Urban populations are more exposed to a sedentary
lifestyle, and it is clear that those populations are at a
higher risk of developing obesity and Type 2 DM
compared with rural populations, which have a higher level
of physical activity. For example, children in the rural
southwestern region of KSA have a lower rate of obesity
(4%), likely due to active lifestyles, such as fishing and
agricultural work; this is unlike the situation for children
N. Alzaman and A. Ali304living in cities in the western (obesity prevalence of 10%) and
eastern provinces (22%), where a sedentary lifestyle and
high-fat, fast food consumption are common.23,24
Other factors associated with obesity are decreased phys-
ical activity and increased time spent on social networking,
video games and television. Cultural factors may further
aggravate the obesity problem. Women face more barriers to
practicing physical activity than men,24 and this may be
aggravated by easy access to cheap migrant labour for
domestic work. For example, nearly all families in Kuwait
and KSA commonly employ cooks and maidsdadding to a
sedentary lifestyle in indigenous women.15,25 Dress has
played a role in obesity as well; women in the Arab world
often wear traditional long and wide dresses that can reduce
their motivation to lose weight.26Genetics of obesity
The understanding of the pathogenesis and factors lead-
ing to obesity has advanced in the past 3 decades. Although
there is a significant multifactorial interaction that leads to
obesity, studies have shown that there is also a significant
contribution from one’s genetic background. The strength of
the genetic factor27 was shown by comparing monozygotic
twins reared apart and those reared together; both sets
showed similar predisposition or predilection to obesity
development. In males reared apart, the correlation was
0.70, and in those reared together, it was 0.74; in women,
the correlation was 0.66 both between those reared apart as
well as those reared together. Comparatively, looking at
dizygotic twins, males reared apart showed a correlation of
0.15, and males reared together showed a 0.33 correlation.
For females, there was a slightly stronger correlation: for
those reared apart, the correlation was 0.25, and for those
reared together, it was 0.27, suggesting a significant genetic
contribution.
The leptin-melanocortin signalling pathway is primarily
controlled by leptin which is produced by adipose tissue. This
regulates satiety and controls energy homoeostasis through
pro-opiomelanocortin (POMC)/cocaine and amphetamine
related transcript (CART) in the melanocortin system.
POMC is cleaved into several peptides, including alpha me-
lanocytes, and hormones that act at the melanocortin 3 and
melanocortin 4 receptor. This is further cleaved by pro-
convertase 1 (PC1) into adrenocorticotropic hormone and
endorphins in addition to melanocyte-stimulating hormone.
Genome-wide association studies of obesity identified the
fat mass and obesity-associated gene FTO.28e31 FTO is
associated with increased BMI and type 2 diabetes. The
association of different polymorphisms with obesity and
diabetes has been documented in several population studies
that include European, Asian, and African children and
adults and has also been associated with abdominal
obesity, waist circumference, and the waist-to-hip ratio.
At least 15 loci32 have been identified in genome-wide
association studies. Several mutations are rare monogenic
causes that are associated with obesity. These are mostly
related to leptin-melanocortin pathways in the regulation of
appetite and energy expenditure. Although monogenic
forms of obesity comprise less than 5% of overall obesity,
the most common forms of monogenic obesity identifiedare those related to the melanocortin 4 receptor
(MC4R).33e37 Of these, the non-syndromic genes associated
with obesity development include leptin, leptin receptor
mutations,38 pro-opiomelanocortin (POMC) mutations,39
proconvertase 1,40 brain-derived neurotrophic factor,41
and single-minded 1(SIM1).42 The syndromes associated
with obesity include PradereWilli syndrome,43 Bardete
Biedl syndrome,44,45 Alstrom syndrome,46 and WAGR
syndrome,41 to name a few. Although more than 200
single gene mutations have been found to be associated
with obesity, most of these occur in only 15 genes.
Overall, these are associated with early onset obesity and
other endocrine and psychiatric disorders.Mechanisms of obesity-associated diabetes mellitus
The influence of obesity on type 2 diabetes risk is deter-
mined not only by the degree of obesity but also by where fat
accumulates. Increased upper body fat, including visceral
adiposity, as reflected in an increased abdominal girth or
waist-to-hip ratio, is associated with metabolic syndrome,
diabetes mellitus, and cardiovascular disease.47,48 Beyond
differences in body fat distribution, emerging evidence
suggests that different subtypes of adipose tissue may be
functionally distinct and affect glucose homoeostasis
differently. Adult humans have limited and variable
numbers of brown fat cells,49 which play a role in
thermogenesis and potentially influence energy expenditure
and obesity susceptibility.50
The interaction between adipose tissue, the adipocyte,
and the response to insulin and insulin resistance is rather
complex. Over the last few decades, several advances have
been made in the field. For nearly a century, inflammation
has been implicated in dysglycaemia, as it was noted that
aspirin administration improved overall glucose control.51
More recently, salicylate has been used and studied to treat
diabetes with minimal success. Several inflammatory
markers51 have been measured and associated with insulin
resistance in the setting of obesity, including interleukin 6,
C-reactive protein, and pleasant plasminogen activator
inhibitor-1, in addition to tumour necrosis factor a (TNF
e a). Intracellular signalling pathways, such as IkBa kinase b
(IKKb) and c-Jun N-terminal kinase 1 (JNK1), may also be
involved. These in turn are thought to be activated by several
substrates related to obesity. In part, these may be activated
by fatty acids that are elevated in obesity and insulin resis-
tance, and possibly by fatty acid metabolites, such as diac-
ylglycerol or ceramides. Inflammation is thought to inhibit
insulin signalling by inhibiting insulin receptor substrate 1
(IRS 1) and PPAR-g, as well increasing the accumulation of
ceramides and diacylglycerol by inhibiting triacylglycerol
synthesis.
Another advance in the area of crosstalk between the
adipocyte and insulin action has been through the discovery
of several different substrates, including adiponectin, which
is one of the major associated substances. Adiponectin is
thought to activate several pathways, including AMPK and
PPAR-a.
In one study by Al-Daghri et al.,45 several SNPs were
associated with the FTO gene in addition to TCF7L2. This
FTO gene variant rs11642841 was associated with
Obesity in Arabs 305increased BMI and waist circumference. Another SNP,
rs7903146, located in the intron region of TCF7L2 was
associated with BMI and waist circumference in both those
with type 2 diabetes and the control group. Additionally, it
was associated with lower HDL levels in type 2 diabetics.
In a study by Zadjali et al.,13 the composition effect of
multiple-trait-associated variance, looking at 36 type 2
diabetes-associated allelic variants, showed a variance of
14% and 19% of hip size and waist circumference, respec-
tively. In Oman, a family-based analysis of genetic variance
of the adiponectin gene was performed in an extended family
for polymorphisms in the promoter region. One of these
SNPs, the rs266729 polymorphism, was associated with
weight, waist circumference, BMI and overall adiposity. It
was also associated with insulin resistance. In Oman,52 one
study evaluated single nucleotide polymorphisms (SNPs)
and the ADIPOQ gene, showing that one variant was
associated with obesity, waist circumference, and to some
degree, insulin sensitivity.
In a Tunisian population,53 there was a significant
association between the E23K variant of the KCNJ11 gene
with type 2 diabetes. In another study by Turki et al.,54
CDKN2A/2B polymorphisms, KCNJ11 polymorphisms
and TCF7L2 were associated with type 2 diabetes in
females, while mutations in the POL1-nearby variant were
associated with type 2 diabetes in males. There was an as-
sociation of this SLC30A8 and TCF7L2 in both genders. The
same group had shown a significant association with the
melanocortin 4 receptor giving rise to risk of type 2 dia-
betes.55 Leptin and leptin receptor mutations have been
shown in Tunisians to be associated with obesity and
metabolic syndrome.56
In another study that investigated gene mutations in both
Lebanese and Tunisian57 populations, TCF7L2 was
associated with an increased risk of diabetes. IGF2BP2 and
PPAR-g were associated with type 2 diabetes in Lebanese,
but not in Tunisians, while KCNJ11 and SLC30A8 were
associated with type 2 diabetes in Tunisians. Additionally,
significant associations between adiponectin gene SNPs
and type 2 diabetes have been found in Tunisians.
Additional mutations or polymorphisms found to be
associated with diabetes in Tunisians were BCL11A,
ADAMTS9, WFS1, CDKAL1, TP53INT1, HNF1A, FTO,
and GCK. Additionally, in Tunisian Arabs, calpain 10
gene variants UCSNP-43, UCSNP-19 and UCSNP-63 were
studied and only UCSNP-1958 was found to contribute to the
risk of diabetes in that population. However, polymorphism
gly1057asp and the IRS2 gene was not found to be associated
with type 2 diabetes and obesity.
In Lebanese population studies, type 2 diabetes was found
to be significantly associated with mutations in the COL8
A1, KCNQ1, ALX 4, and HNF-1 loci.57,59e62 However,
FTO, ADAMTS9, and WFS1 associations with type 2
diabetes were lost with multiple testing corrections.
Another analysis did not show an association with
exostosin-2 or EXT2 gene variants with type 2 diabetes.63
Another gene associated with increased risk is IGF2BP2.
In KSA populations, several tests have been performed to
evaluate the variance in the vitamin D receptor (VDR) gene
with different components of metabolic syndrome.64 One
variant was associated with lower HDL levels and obesity.
Another variant was found to be associated with diabetes,and another was associated with a reduced risk of diabetes.
In the study mentioned previously by Al-Daghri et al.,7
several variants were found to be associated with type 2
diabetes, including WFS1, JAZF1, SLC30A8, CDKN 2A/
B, TCF7L2, KCNQ1, HMG20A, HNF4A, and DUSP-9.
Also in a KSA population, the E23K variant of the
KCNJ11 gene showed a significant association with diabetes
mellitus type 2.
Obesity complications
Morbidity and mortality65,66 resulting from obesity have
been demonstrated in several studies. Obesity is a risk
factor for diabetes mellitus as well as other chronic
diseases. Impaired glucose tolerance is also a risk factor for
developing diabetes and is associated with obesity. In a
study of more than 6000 students in the sixth grade
(average age 11.8 years), nearly 20 percent were overweight
and 30 percent were obese.67 Impaired fasting glucose
(fasting blood glucose 100 mg/dL) was present in 15
percent of overweight children, 20 percent of obese
children, and 22 percent of severely obese children.
Hypertension is another condition associated with
obesity, in a report from the Nurses’ Health Study,68 BMI at
age 18 years and at midlife was positively associated with
hypertension. Weight gain was also associated with an
increased risk; the relative risk of hypertension in those
women who gained 5.0e9.9 kg and 25.0 kg was 1.7 and
5.2, respectively.
Limited data are available regarding the complications of
obesity within Arabs. Elkum et al.69 reported a strong
association between breast cancer and obesity among Arab
females (OR ¼ 2.29, 95% CI 1.68e3.13). The proportion
of overweight/obese (BMI 25) females was significantly
higher among breast cancer patients (75.8%) than among
healthy controls (61.3%). Another group in UAE70 found
that majority of patients with obstructive sleep apnea and
obesity hypoventilation syndrome had BMI 30 which
increased their risk for cardiovascular disease as well as
pulmonary hypertension. Musaiger et al.71 found that
obese women were at higher risk for diabetes, hypertension
and osteoarthritis.
Management: diet, medications and surgery
With the advent and understanding of different central
mechanisms, most notably in the hypothalamus and the
ventromedial nucleus, several new medications have been
approved for use, in addition to those previously approved.72
These include noradrenergic medications, which suppress
appetite. A serotonin-norepinephrine reuptake inhibitor73
(Sibutramine) as well as an inverse agonist to cannabinoid
receptor CB174,75 (Rimonabant) had been approved, but
due to increased cardiovascular events76 with the former
and suicidality77 in the latter, these were removed from the
market. These medications are limited in the Arab world,
specifically in KSA, and have not been approved and are
not in use clinically.
Similarly, the combination of phentermine with top-
iramate78e80 has received approval by the FDA in the United
States. This combination has noradrenergic effects as well as
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with only modest weight loss. Another combination, bupro-
pion with naltrexone,81,82 was also approved. Similarly,
bupropion has noradrenergic effects by inhibiting reuptake,
with some blocking effects at the nicotinic receptors, with
naltrexone as an opioid antagonist further potentiating the
action of bupropion. Lastly, lorcaserin83e85 was also
approved, which is a selective 5-hydroxy tryptophan (5-
HT2C) receptor agonist. It is that selectivity which will pre-
vent formation of the valvular lesions seen with its prede-
cessor, fenfluramine.86
With advances in gut-peptide and nervous system in-
teractions, liraglutide,87,88 a GLP-1 receptor agonist, has also
been approved for use in the medical management of
diabetes.
Overall, medical management of obesity has shown
limited progress due to the modesty of the associated weight
loss in relation to numerous side effects. Weight-loss sur-
geries have thus been the cornerstone of obesity manage-
ment, internationally and in the Arab world.
Several studies have been conducted throughout the Arab
world investigating the outcomes of surgical interventions for
weight loss. In one study, children younger than 1489
underwent laparoscopic surgical sleeve gastrectomy and the
outcomes showed significantly higher growth and fewer
comorbidities, but similar resolution rights compared to
nonsurgical weight management. Another study was
conducted in children and adolescents with PradereWilli
syndrome,90 which showed effective weight loss and
improvement in overall comorbidities without increased
mortality or significantmorbidity or changes in rate of growth.
In a single centre study in the United Arab Emirates,91
patients’ outcomes over a year were evaluated. The most
frequent procedure was a Roux-en-Y gastric bypass, and
the outcomes showed improvement in the triglyceride levels,
like the heated haemoglobin levels, with expected weight
loss.
Obese children and adolescents92 undergoing sleeve
gastrectomy showed no recurrence up to 3 years after
surgery and only some comorbidities. There was resolution,
remission or improvement in more than 90% of
comorbidities at 2 years with few complications, no
mortality and normal growth.
In a study in the Northern West Bank,93 the outcomes of
bariatric surgery showed improvement in systolic blood
pressure, fasting blood sugar and glycated haemoglobin,
along with the expected weight loss. In a study in the
United Arab Emirates,94 comparing bariatric or weight-
loss surgery with international programs showed that
Roux-en-Y gastric bypass and sleeve gastrectomy were per-
formed more frequently and fewer laparoscopic adjustable
gastric bandings were performed. There were lower septic
cardiac and renal failure complications.
The most common bariatric procedures include Roux-en-
Y gastric bypass, sleeve gastrectomy, and adjustable gastric
band, though the latter is becoming less popular overall due
to complications, modesty of weight loss compared to the
other 2 procedures, and the need for frequent doctor visits.
Studies in the Arab world have showed similar outcomes
compared to international standards, though the published
data are limited. Anecdotally, one would assume these pro-
cedures are performed at quite high rates, given theprevalence of obesity in the region. Additionally, these pro-
cedures have been used in adolescents and in some subgroups
with syndromic obesity. These studies have been able to
show weight loss, but long-term outcomes are lacking in the
subgroups.
The EndoBarrier95e97 was recently approved in the US
and had been previously approved in Europe, and it is very
likely to gain popularity given its simplicity, effectiveness
and reversibility.Barriers to management
A vast majority of barriers, ranging from deficits in
research to socioeconomic and individual psychological
factors, undermine current efforts to manage obesity.
Absence of health care awareness, absence of medications
approved to treat obesity, lack of patient education, weight
gain associated with diabetes medications, depression asso-
ciated with diabetes, and difficulty to attain weight loss
because of cultural and social barriers are important key
factors. There appears to be a lack of public awareness of
healthy eating habits and the benefits of physical activity.98
In providers, there also appears to be a lack of awareness
of the link between obesity and diabetes and the
importance of managing obesity to control diabetes.
A meta-analysis by Waters et al.99 of 55 studies assessing
educational, behavioural, and health promotion
interventions in children aged 0e18 years found that these
interventions reduced BMI (standardized mean difference
in adiposity, 0.15 kg/m2). The study concluded that child
obesity prevention programs have beneficial effects.
Educational programs targeting children at the primary-
and middle-school level would be one of the most important
ways to increase such awareness at young age. Each patient is
different in terms of their education, social status and family
status; a patient-centred approach is another successful way
to combat obesity.Conclusion
Obesity is a complex disorder. It is a crisis that is
impacting health care in the Arab nations of the Middle
East and in north and west Africa; six countries in this re-
gion are on the top-ten list worldwide in terms of diabetes
and obesity prevalence. Comprising 22 countries with a total
population of 350 million people, these nations constitute
only approximately 5% of the total world population; yet,
nearly 20% of the people in Kuwait, Lebanon, Qatar, KSA,
and the United Arab Emirates (UAE) are diabetic. Most
patients with diabetes are obese; it is therefore critical to
understand the relationship between obesity and the devel-
opment of diabetes. Several aspects have been identified and
addressed internationally, but there is a significant lack of
data from the Arab region; additionally, the paucity of
modalities available to treat obesity in the Arab world need
to be addressed.Conflict of interest
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